Argo Biopharma Named to Fast Company's Annual List of the World’s Most Innovative Companies of 2026
Learn MoreArgo Biopharma Receives FDA Fast Track Designation for BW-20805, an Investigational siRNA Therapy for the Treatment of HAE
Learn MoreArgo Biopharma Appoints Dr. Gena Wang as Chief Financial Officer and Chief Strategy Officer
Learn MoreArgo Biopharma to Present Positive Phase II Interim Results of siRNA Therapeutic BW-20805 for HAE at the 2026 AAAAI Annual Meeting
Learn MoreArgo Biopharma Announces First Patient Dosed in Phase 2b Trial of siRNA Therapeutic BW-20829 in Patients with Elevated Lp(a)
Learn MoreArgo Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
Learn MoreArgo Biopharma to Present Positive Phase I Results of siRNA Therapeutic BW-20805 for HAE at ACAAI 2025
Learn More为了更好的呈现效果,移动端请竖屏浏览